Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
1999 3
2001 4
2002 5
2003 3
2004 5
2005 7
2006 4
2007 5
2008 4
2009 5
2010 5
2011 8
2012 9
2013 12
2014 13
2015 9
2016 8
2017 11
2018 12
2019 8
2020 3
2021 8
2022 6
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Dimopoulos MA, et al. Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5. Lancet Oncol. 2021. PMID: 34087126 Clinical Trial.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Dimopoulos MA, et al. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1. N Engl J Med. 2018. PMID: 29856685 Free article. Clinical Trial.
A revised international prognostic score system for Waldenström's macroglobulinemia.
Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA. Kastritis E, et al. Among authors: kyrtsonis mc. Leukemia. 2019 Nov;33(11):2654-2661. doi: 10.1038/s41375-019-0431-y. Epub 2019 May 22. Leukemia. 2019. PMID: 31118465
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
Nodal marginal zone lymphoma.
Angelopoulou MK, Kalpadakis C, Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP. Angelopoulou MK, et al. Among authors: kyrtsonis mc. Leuk Lymphoma. 2014 Jun;55(6):1240-50. doi: 10.3109/10428194.2013.840888. Epub 2013 Nov 12. Leuk Lymphoma. 2014. PMID: 24004184 Review.
New insights into monoclonal B-cell lymphocytosis.
Kalpadakis C, Pangalis GA, Sachanas S, Vassilakopoulos TP, Kyriakaki S, Korkolopoulou P, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Kyrtsonis MC, Levidou G, Papadaki HA, Panayiotidis P, Angelopoulou MK. Kalpadakis C, et al. Among authors: kyrtsonis mc. Biomed Res Int. 2014;2014:258917. doi: 10.1155/2014/258917. Epub 2014 Sep 11. Biomed Res Int. 2014. PMID: 25295254 Free PMC article. Review.
New insights into malignant B-cell disorders.
Kyrtsonis MC, Shimizu K, Panayiotidis P, Pangalis GA. Kyrtsonis MC, et al. Biomed Res Int. 2015;2015:128084. doi: 10.1155/2015/128084. Epub 2015 Jan 28. Biomed Res Int. 2015. PMID: 25695044 Free PMC article. No abstract available.
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
Kastritis E, Terpos E, Symeonidis A, Labropoulou V, Delimpasi S, Mancuso K, Zamagni E, Katodritou E, Rivolti E, Kyrtsonis MC, Roussou M, Fotiou D, Theodorakakou F, Ntanasis-Stathopoulos I, Hatjiharissi E, Kanellias N, Migkou M, Cheliotis G, Manousou K, Gavriatopoulou M, Dimopoulos MA. Kastritis E, et al. Among authors: kyrtsonis mc. Am J Hematol. 2023 Sep;98(9):E226-E229. doi: 10.1002/ajh.27001. Epub 2023 Jun 21. Am J Hematol. 2023. PMID: 37340832 Clinical Trial. No abstract available.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
145 results